VYCO VYCOR MEDICAL INC
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1424768 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-10.2%
TTM net income YoY-289.2%
TTM EPS YoY0.0%
Revenue 3-yr CAGR6.3%
Net income 3-yr CAGR—
Margins
Gross margin82.4%
Operating margin2.5%
Net margin-3.8%
FCF margin—
EBITDA margin6.0%
Returns
ROE—
ROA-6.7%
ROIC (approx.)—
Asset turnover1.79x
Leverage & solvency
Liabilities / assets557.3%
Debt / equity—
Current ratio0.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.18x
Accruals ratio-21.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.86M | $1.59M |
| Cost of revenue | $302,293 | $166,809 |
| Gross profit | $1.56M | $1.42M |
| R&D expense | $9,963 | $15,325 |
| SG&A expense | $1.46M | $1.36M |
| Operating income | $33,900 | -$9,145 |
| Pretax income | -$70,190 | -$106,951 |
| Net income | -$72,426 | -$107,200 |
| EBITDA | $93,421 | $50,376 |
| EPS (basic) | -0.01 | -0.01 |
| EPS (diluted) | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 33.37M | 32.88M |
| Balance sheet | ||
| Cash & equivalents | $86,982 | $105,648 |
| Receivables | $218,891 | $245,260 |
| Inventory | $159,202 | $146,084 |
| Current assets | $563,422 | $619,614 |
| PP&E, net | $133,936 | $192,693 |
| Total assets | $830,420 | $998,117 |
| Current liabilities | $4.78M | $4.50M |
| Total liabilities | $4.92M | $4.69M |
| Shareholders' equity | -$4.09M | -$3.69M |
| Shares outstanding | 33.37M | 33.37M |
| Cash flow statement | ||
| Operating cash flow | -$13,471 | $60,110 |
| Capital expenditure | $5,224 | $5,366 |
| Free cash flow | -$18,695 | $54,744 |
| Investing cash flow | -$4,383 | -$4,199 |
| Financing cash flow | -$812 | -$7,554 |
| Depreciation & amortization | $59,521 | $59,521 |
| Stock-based compensation | $48,838 | $26,783 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.